leisure time -WSS

leisure time

author：explore 2025-09-29 20:53:28 - browse：83844

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： How the drug

knowledge

WSS

Measles policy set amid Florida outbreak alarms vaccine proponents

Reporting on presidential health from Reagan to Trump and Biden

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Opioid cravings were reduced by anti

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

entertainment

leisure time

focus

Continuity nursing helped my family in our darkest PICU moments

Researchers tackle phage therapy hurdles for wider adoption

Hepatitis C has a cure — but many Americans still lack access to it

Measles policy set amid Florida outbreak alarms vaccine proponents

Hollywood unions extend contract negotiations for actors

Measles policy set amid Florida outbreak alarms vaccine proponents

Cancer drug shortages should be causing more outrage

People can get long Covid without testing positive for virus: Study

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

entertainment

Abortion policy in the spotlight at Republican debate

Can U.S. cancer drug shortages be fixed?

Medicare Advantage enrollment grows 7.1% to 33.4 million people

New CMS data security rules will hurt Medicare, Medicaid research

How to make over

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

knowledge

entertainment

hotspot

hotspot